midsize biotech
-
トランプ「最恵国薬価」政策、対象26社のリスト
AbbVie, Alcon, amgen, Astellas, AstraZeneca, BeOne Medicines, Biotech, Boehringer Ingelheim, BridgeBio, Bristol Myers Squibb, CSL, drug price reform, drug pricing, Eli Lilly, EMD Serono, Genentech, Gilead Sciences, GLP-1, GSK, healthcare affordability, healthcare policy, Japan pharma, Johnson & Johnson, Kyowa Kirin, MAHA, Medicaid, Merck, MFN, midsize biotech, Midsized Biotech Alliance of America, midterm elections, Most Favored Nation, novartis, novo nordisk, pfizer, pharma stocks, Pharmaceutical Industry, PhRMA, Regeneron, RFK Jr., Robert F. Kennedy Jr., sanofi, Sun Pharma, Takeda, tariffs, TEVA, Trump, TrumpRx, UCB, US politics
トランプ大統領の「最恵国薬価」政策により、2026年8月31日までに26社がアメリカの薬価を国際基準に合わせる…
Ken リクルターブログ 